The global high potency API contract manufacturing market is anticipated to reflect considerable growth rate across the forecast period. The relative amount of novel drug candidates that are highly potent is constantly increasing, leading to greater demand for additional manufacturing capabilities. To meet such exceeding demand, the CMOs with specialized capacities in the development of active pharmaceutical ingredients are helping to tackle this issue across the industry.
Significant barriers for the pharmaceutical companies across the high potency API (HPAPI) manufacturing industry are associated with the complications of equipment handling process and significant cost of investments. Majority of the small sized companies are facing a dearth in resources to install in-house HPAPI development capabilities. Furthermore, few large-scale companies have selectively invested only on commercial scale or late stage drug manufacturing capabilities, favoring to rely on outsourcing services for the earlier stages of drug development or research based manufacturing activities. Hence, with the growing adoption of contract manufacturing services, the HPAPI development is witnessing a transition towards the outsourcing facilities, thus reflecting a substantial momentum in the global HPAPI contract manufacturing market.
The COVID-19 restrictions had disrupted the pharmaceutical supply chain and completely halted the research based activities, which has directly impacted the, production of HPAPI. However, with the ease of restrictions in the second half of 2020 and substantial economic recovery, the market is projected to witness lucrative growth over the forecast period.
The oncology segment is anticipated to hold the highest market share in the high potency API contract manufacturing market owing to increasing research on novel cancer drug therapies. For instance, as per IQVIA, the late stage oncology pipeline in 2018 included 849 HPAPI molecules, reflecting a growth of around 77% since 2008, due to the growing number of targeted drug therapies.
The market in Asia Pacific region is expected to witness the most lucrative growth over the forecast period, owing to the high presence of countries such as China in the pharmaceutical industry. China is the world’s largest manufacturer of all kinds of APIs and as per the Convention on Pharmaceutical Ingredients (CPHI), Chinese manufacturers make around 40% of all APIs used globally.
The key global industry players across the market includes Piramal Pharma, Lonza, Catalent Inc, VxP Pharma, Inc., Pfizer, Gentec Pharmaceutical Group, AbbVie and few others.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."